Company intelligence / Profile preview

Nanogrow Biotech

Cizur, Navarra, Spainx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Nanogrow is developing nanoantibody-based biological treatments with a focus on localized therapies that have fewer side effects. They have worked with over 100 antigens and are currently in pre-clinical development stages.

Therapeutic areas: OncologyDermatology
Modalities: Nanoantibodies (Single-Domain Antibodies/SdAbs)
Industry: Biotech

Drug pipeline

1 asset

PD-1 nanobody (AAV delivery)

Preclinical

Partnerships

Collaboration with Cima

Beyond the preview

Go deeper on Nanogrow Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanogrow Biotech.

Explore the full profile